Published • loading... • Updated
New Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function
- The SUPER 2 study published in Nature Communications found that Efsubaglutide Alfa improved glycaemic control in adults with type 2 diabetes on metformin and enhanced β-cell function.
- Academician Weiping Jia led the study, with Professor Qinghua Wang, founder of Innogen Pharmaceuticals and inventor of Efsubaglutide Alfa, as co-corresponding author.
- SUPER 2 was a randomized, double-blind, placebo-controlled phase IIb/III trial assessing Efsubaglutide Alfa as an add-on therapy to metformin in type 2 diabetes patients.
- Efsubaglutide Alfa significantly improved HbA1c and other key glycaemic measures with mostly mild-to-moderate gastrointestinal side effects.
Insights by Ground AI
22 Articles
22 Articles
Coverage Details
Total News Sources22
Leaning Left5Leaning Right2Center9Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 31%
C 56%
13%
Factuality
To view factuality data please Upgrade to Premium
